Today, the CFO & CAO of Vivus (VVUS), Mark Oki, bought shares of VVUS for $40.7K.
Following this transaction Mark Oki’s holding in the company was increased by 100% to a total of $39.8K.
See today’s analyst top recommended stocks >>
Based on Vivus’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $18.09 million and GAAP net loss of $9.22 million. In comparison, last year the company earned revenue of $15.19 million and had a GAAP net loss of $5.99 million. Currently, Vivus has an average volume of 46.59K.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. Its products include Qsymia and STENDRA/SPEDRA. The company was founded by Virgil A. Palace in April 16, 1991 and is headquartered in Mountain View, CA.
